Royalty Investor Debt Tops Par
A $1.4 billion term loan for Royalty Pharma broke in the secondary market last week and was trading around 100 1/2-3/4 last Wednesday, according to a dealer.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: